

B³ cont'd.
colon cancer cell.

55. The antibody of Claim 47 which is cross-linked to a homologous DR4 antibody. --

REMARKS

In the Office Action, the Examiner issued a Restriction Requirement under 35 USC 121, requiring restriction of pending claims 1-32 to one of four groups (I-IV). Applicants hereby elect to prosecute the claims drawn to Group I in the present application. Claims 22 and 25-32 have been canceled without prejudice in the above amendment as being drawn to the non-elected inventions. Applicants reserve the right to prosecute claims directed to these non-elected inventions in further continuing applications. A clean copy of the now pending claims 1-21, 23-24 and 33-55 is provided herewith in Attachment A.

Claims 1 and 23 have been amended to further clarify the recited antibodies, and claims 33-55 have been added. Support for the amended and added claims can be found on at least pages 9, 12-14, 16-17, 19, and 27-29 of the specification. Accordingly, it is believed that no new matter has been introduced.

Respectfully submitted,
GENENTECH, INC.

Dated: December 29, 2000

By: *Diane L. Marschang*
Diane L. Marschang
Attorney for the Applicants
Reg. No. 35,600

1 DNA WAY
So. San Francisco, CA 94080-4990
Phone: (650) 225-5416
Fax: (650) 952-9881

ATTACHMENT A

1. An isolated antibody which specifically binds to DR4 polypeptide comprising amino acid residues 24 to 218 of Figure 1 (SEQ ID NO:1).
2. The antibody of Claim 1 which is an agonist antibody.
3. The antibody of Claim 1 which is a blocking antibody.
4. The antibody of Claim 1 which is a monoclonal antibody.
5. The antibody of Claim 1 which is a murine antibody.
6. The antibody of Claim 1 which is a humanized antibody.
7. The antibody of Claim 1 which is a chimeric antibody.
8. The antibody of Claim 1 which is a monomeric antibody.
9. The antibody of Claim 1 which is a multivalent antibody.
10. A hybridoma cell line which produces the antibody of Claim 4.
11. The antibody of Claim 4 having the same biological characteristics of (1) the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-12695; (2) the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-12694; or (3) the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC PTA-99.
12. The antibody of Claim 4 wherein the antibody binds to the same epitope as (1) the epitope to which the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-12695 binds; (2) the epitope to which the monoclonal antibody produced by the hybridoma cell line deposited under the American Type Culture Collection Accession Number ATCC HB-12694 binds; or (3) the epitope to which the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC PTA-99.
13. The hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-12695.
14. The hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-12694.
15. The hybridoma cell line deposited under American Type Culture

Collection Accession Number ATCC PTA-99.

16. The monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-12695.

17. The monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-12694.

18. The monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC PTA-99.

19. An isolated nucleic acid comprising DNA encoding the DR4 antibody of Claim 1.

20. A composition comprising the antibody of Claim 1 and a carrier.

21. The composition of claim 20 wherein said carrier is a pharmaceutically acceptable carrier.

23. An article of manufacture, comprising a container and a composition contained within said container, wherein the composition includes the DR4 antibody of claim 1.

24. The article of manufacture of Claim 23 further comprising instructions for using the DR4 antibody *in vivo* or *ex vivo*.

33. An isolated antibody which binds to DR4 polypeptide comprising amino acid residues 24 to 218 of Figure 1 (SEQ ID NO:1) and which induces apoptosis in at least one type of mammalian cancer cell.

34. The antibody of Claim 33 which is a monoclonal antibody.

35. The antibody of Claim 33 which is a human antibody.

36. The antibody of Claim 33 which is a humanized antibody.

37. The antibody of Claim 33 which is a chimeric antibody.

38. The antibody of Claim 33 wherein said mammalian cancer cell expresses DR4 polypeptide.

39. The antibody of Claim 33 wherein said mammalian cancer cell is a lung cancer cell.

40. The antibody of Claim 33 wherein said mammalian cancer cell is a colon cancer cell.

41. The antibody of Claim 33 which is cross-linked to a homologous DR4 antibody.

42. An isolated antibody which binds to DR4 polypeptide comprising amino acid residues 24 to 218 of Figure 1 (SEQ ID NO:1) and which blocks binding of Apo-2 ligand to said DR4 polypeptide.
43. The antibody of Claim 42 which is a monoclonal antibody.
44. The antibody of Claim 42 which is a human antibody.
45. The antibody of Claim 42 which is a humanized antibody.
46. The antibody of Claim 42 which is a chimeric antibody.
47. An isolated antibody which binds to DR4 polypeptide comprising amino acid residues 24 to 218 of Figure 1 (SEQ ID NO:1) and which blocks Apo-2 ligand induced apoptosis in at least one type of mammalian cancer cell.
48. The antibody of Claim 47 which is a monoclonal antibody.
49. The antibody of Claim 47 which is a human antibody.
50. The antibody of Claim 47 which is a humanized antibody.
51. The antibody of Claim 47 which is a chimeric antibody.
52. The antibody of Claim 47 wherein said mammalian cancer cell expresses DR4 polypeptide.
53. The antibody of Claim 47 wherein said mammalian cancer cell is a lung cancer cell.
54. The antibody of Claim 47 wherein said mammalian cancer cell is a colon cancer cell.
55. The antibody of Claim 47 which is cross-linked to a homologous DR4 antibody.